FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 305:545-551 September 3, 1981 Number 10 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We randomized 96 postmenopausal women with metastatic breast carcinoma to receive surgical adrenalectomy or medical therapy with an adrenal inhibitor, aminoglutethimide (AG), plus replacement hydrocortisone. Before randomization, women were stratified according to disease-free interval, site of dominant disease, and estrogen-receptor status. Of 40 evaluable women treated with AG and hydrocortisone, 53 per cent had objective responses, as compared with 45 per cent of 29 women undergoing surgical adrenalectomy (P value not significant). Responses lasted a mean of 17.2 months in the medical group and greater than 17.1 months in the surgical group (not significant). Estrogen levels fell similarly in response to either treatment, whereas AG and hydrocortisone preserved androgen production. A null hypothesis tested the single question asked by this study: "Is surgical adrenalectomy superior to treatment with AG and hydrocortisone?" Rejection at significance levels of P = 0.01 and P = 0.07 for differences of 20 per cent and 10 per cent, respectively, suggested that medical therapy with AG and hydrocortisone may be logically chosen in place of surgical adrenalectomy.

This article has been cited by other articles:

• Bross, P. F., Baird, A., Chen, G., Jee, J. M., Lostritto, R. T., Morse, D. E., Rosario, L. A., Williams, G. M., Yang, P., Rahman, A., Williams, G., Pazdur, R. (2003). Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. Clin. Cancer Res. 9: 4309-4317 [Abstract] [Full Text]  
• Schmid, M., Jakesz, R., Samonigg, H., Kubista, E., Gnant, M., Menzel, C., Seifert, M., Haider, K., Taucher, S., Mlineritsch, B., Steindorfer, P., Kwasny, W., Stierer, M., Tausch, C., Fridrik, M., Wette, V., Steger, G., Hausmaninger, H. (2003). Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6. JCO 21: 984-990 [Abstract] [Full Text]  
• Buzdar, A. U. (2003). Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors. Clin. Cancer Res. 9: 468S-472S [Abstract] [Full Text]  
• Song, R. X.-D., Mor, G., Naftolin, F., McPherson, R. A., Song, J., Zhang, Z., Yue, W., Wang, J., Santen, R. J. (2001). Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17{beta}-Estradiol. JNCI J Natl Cancer Inst 93: 1714-1723 [Abstract] [Full Text]  
• Johnson, A G, Dixon, J M. (1997). Removing bias in surgical trials. BMJ 314: 916-916 [Full Text]